# Dermatitis, Atopic FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/dermatitis-atopic

> 7 upcoming FDA catalysts in dermatitis, Atopic: JNJ-95597528 (JNJ) on November 2026 (primary completion); amlitelimab (SNY) on Sep to Dec 2027 (topline data readout); amlitelimab (SNY) on September 2027 (primary completion); dupilumab coformulated with berahyaluronidase alfa (SNY) on May to Aug 2028 (topline data readout); and 3 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 23, 2025 | [GSK1070806 primary completion](https://sec-api.dev/pdufa/gsk1070806) | GSK | Dermatitis, Atopic | withdrawn | "NCT05999799 (A Dose Finding Study to Investigate the Safety and Effectiveness of GSK1070806 in Adult Participants With Moderate to Severe Atopic Dermatitis): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-23 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-03." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05999799)) |
| July 23, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06130566 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-23 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06130566)) |
| July 29, 2025 | [GSK1070806 primary completion](https://sec-api.dev/pdufa/gsk1070806) | GSK | Dermatitis, Atopic | withdrawn | "NCT06447506 (Long-Term Study (AtDvance) to Evaluate GSK1070806 in Atopic Dermatitis.): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-07-29 (ACTUAL); Lead Sponsor GlaxoSmithKline; Results First Posted 2026-06-16." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06447506)) |
| August 21, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06224348 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-21 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06224348)) |
| October 1, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06015308 (A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06015308)) |
| November 25, 2025 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06181435 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-25 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06181435)) |
| December 22, 2025 | [Cibinqo (abrocitinib) primary completion](https://sec-api.dev/pdufa/abrocitinib) | PFE | Dermatitis, Atopic | completed | "NCT03422822 (Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-22 (ACTUAL); Lead Sponsor Pfizer." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03422822)) |
| February 12, 2026 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Dermatitis Atopic | completed | "NCT06790121 (A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2026-02-12 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06790121)) |
| March 26, 2026 | [JNJ-95475939 primary completion](https://sec-api.dev/pdufa/jnj-95475939) | JNJ | Dermatitis, Atopic | withdrawn | "NCT06881251 (A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD)): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-03-26 (ACTUAL); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06881251)) |
| June 10, 2026 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | completed | "NCT06407934 (A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-10 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06407934)) |
| Nov 2026 to Feb 2027 | [JNJ-95597528 topline data readout](https://sec-api.dev/pdufa/jnj-95597528) | JNJ | Dermatitis, Atopic | scheduled | "NCT07230860 (A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07230860)) |
| November 2026 | [JNJ-95597528 primary completion](https://sec-api.dev/pdufa/jnj-95597528) | JNJ | Dermatitis, Atopic | scheduled | "NCT07230860 (A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-19 (ESTIMATED); Lead Sponsor Janssen Research & Development, LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07230860)) |
| Sep to Dec 2027 | [Amlitelimab topline data readout](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | scheduled | "NCT06241118 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06241118)) |
| September 2027 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | scheduled | "NCT06241118 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06241118)) |
| May to Aug 2028 | [Dupilumab coformulated with berahyaluronidase alfa topline data readout](https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa) | SNY | Dermatitis Atopic | scheduled | "NCT07919899 (Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-05-02 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07919899)) |
| May 2028 | [Dupilumab coformulated with berahyaluronidase alfa primary completion](https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa) | SNY | Dermatitis Atopic | scheduled | "NCT07919899 (Pharmacokinetics, Immunogenicity and Safety of Subcutaneous Dupilumab and Berahyaluronidase Alfa (ALT-B4) Coformulation): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2028-05-02 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07919899)) |
| Jan to Apr 2029 | [Amlitelimab topline data readout](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | scheduled | "NCT05492578 (Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05492578)) |
| January 2029 | [Amlitelimab primary completion](https://sec-api.dev/pdufa/amlitelimab) | SNY | Dermatitis Atopic | scheduled | "NCT05492578 (Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01-22 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05492578)) |

## Drugs

- [GSK1070806](https://sec-api.dev/pdufa/gsk1070806) (GSK)
- [Amlitelimab](https://sec-api.dev/pdufa/amlitelimab) (SNY)
- [Cibinqo (abrocitinib)](https://sec-api.dev/pdufa/abrocitinib) (PFE)
- [Lunsekimig](https://sec-api.dev/pdufa/lunsekimig) (SNY)
- [JNJ-95475939](https://sec-api.dev/pdufa/jnj-95475939) (JNJ)
- [JNJ-95597528](https://sec-api.dev/pdufa/jnj-95597528) (JNJ)
- [Dupilumab coformulated with berahyaluronidase alfa](https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa) (SNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/dermatitis-atopic.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Dermatitis, Atopic FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/dermatitis-atopic

```bibtex
@misc{secapidev_indications_dermatitis_atopic_20261116,
  title        = {Dermatitis, Atopic FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/dermatitis-atopic}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_dermatitis_atopic_20261116","title":"Dermatitis, Atopic FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/dermatitis-atopic","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
